On December 31, 2025, Outlook Therapeutics, Inc. received a complete response letter from the FDA regarding its application for ONS-5010, aimed at treating wet AMD.
AI Assistant
OUTLOOK THERAPEUTICS INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.